



World leader in GPCR drug discovery and early development

Proprietary GPCR-targeted **StaR® technology** and SBDD platform capabilities

Japan-anchored biotech, with state-of-the-art R&D center in Cambridge, UK

Listed on Tokyo Stock Exchange (4565-JP)



200+
EMPLOYEES
WORLDWIDE



340+
STRUCTURES
SOLVED



500+
GLOBAL
PATENTS



15+
WORLD-LEADING
PARTNERS




\$800M+
PARTNER REV.
RECEIVED TO DATE¹

¹Includes upfront and milestone payments, royalties and R&D funding received from active, inactive and completed partnerships from 2005 to 2021.

EVOLVING WITH A SPECIALIST THERAPEUTIC FOCUS

Advancing a broad and deep pipeline of **over 40** partnered and in-house drug candidates across multiple therapeutic areas, including:

- Neurology
- Immunology
- Gastroenterology
- Other



TECHNOLOGY & PLATFORM

Sosei Heptares has developed a unique and powerful platform technology capability called StaR® (Stabilized Receptor) that, for the first time, enables powerful structure-based drug design (SBDD) approaches to be applied to functional, stabilized GPCRs.

DRUG DISCOVERY

Sosei Heptares' StaR®/SBDD platform capabilities allow us to develop better, differentiated drug candidates against established and emerging novel GPCR target mechanisms. Our highly productive discovery engine has generated 25 high quality novel preclinical candidates and produced ten IND clinical candidates in the last 12 years. This rate is well above industry averages.

EARLY DRUG DEVELOPMENT

Sosei Heptares has fully established early development teams in the UK and Japan. Multiple clinical and non-clinical programs are underway both in-house and through our partnerships with leading global pharma companies.

PRODUCT PIPELINE

	Product/Program	Modality ¹	Indication	Partner	Collaboration Type
Marketed Products	Seebri® Breezhaler®	SME	COPD	NOVARTIS	Royalty
	Ultibro® Breezhaler®	SME	COPD	NOVARTIS	Royalty
	Enerzair® Breezhaler®	SME	Asthma	NOVARTIS	Royalty
	ORAVI®	SME	Oropharyngeal candidiasis	Hisamitsu	Product Sales
Phase 2	A _{2A} antagonist combo	SME	mCRPC	AstraZeneca	Out-licensed
Phase 1	GLP-1 agonist	SME	T2DM/Obesity	Pfizer	Out-licensed
	CCR6 antagonist	SME	Inflammatory bowel disease	Pfizer	Out-licensed
	MC4 antagonist	SME	Anorexia	Pfizer	Out-licensed
	CGRP antagonist	SME	CGRP-mediated conditions	Biohaven	Out-licensed
	mGlu ₅ NAM	SME	Substance Use Disorders	Tempo Bio	Asset centric company
	M ₄ agonist	SME	Major neurological disorders	Neurocrine	Out-licensed
	M ₁ agonist ²	SME	Major neurological disorders	Neurocrine	Out-licensed
Preclinical	M ₁ /M ₄ agonist	SME	Major neurological disorders	Neurocrine	Out-licensed
	GPR35 agonist	SME	Inflammatory bowel disease	esk	Out-licensed
	CXCR4 mAb	mAb	Immuno-oncology	kymab SANOFI	Co-development
	H4 antagonist	SME	Atopic Dermatitis	SOSEI HEPTARES	In-House (Pre-partnered)
	EP4 antagonist	SME	Immuno-oncology	SOSEI HEPTARES	In-House (Pre-partnered)
	GPR52 agonist	SME	Neurology diseases	SOSEI HEPTARES	In-House (Pre-partnered)
	EP4 agonist	SME	Inflammatory bowel diseases	SOSEI HEPTARES	In-House (Pre-partnered)
Discovery	Multi-target	SME/LME	Multiple indications	Genentech <small>a Member of the Roche Group</small>	Out-licensed
	Multi-target	SME/LME	Gastrointestinal and other	Takeda	Out-licensed
	Multi-target	SME	Multiple indications	Pfizer	Out-licensed
	Single target	SME	Inflammatory diseases	abbvie	Out-licensed
	Single target	Peptide	Inflammatory diseases	Northman	Co-development
	TPD ³	SME	Gastrointestinal disorders	Captor Therapeutics	Co-development
	AI drug discovery	SME	Neurology diseases	PHARMENABLE	Co-development
	AI drug discovery	SME/LME	Immune diseases	Inveni AI	Co-development
	AI drug discovery	SME/LME	Immune diseases	verily	Co-development
	Ion Channel	SME	Neurology diseases	metrion	Co-development
	Antibody Discovery	mAb	Disease-relevant GPCR targets	T W I S T	Co-development
	Orexin agonists	SME	Narcolepsy	Orexia Therapeutics CENTESSA	Asset centric company
	SARS CoV-2 Mpro	SME	Coronaviruses	SOSEI HEPTARES	In-House (Pre-partnered)
PAR2	mAb	Atopic dermatitis	SOSEI HEPTARES	In-House (Pre-partnered)	
In-house Targeting academic/ industrial partnership	SSTR ₅ agonist	Peptide	Hypoglycaemic disorders	SOSEI HEPTARES	In-House (Pre-partnered)
	GLP-1 antagonist	Peptide	Hypoglycaemic disorders	SOSEI HEPTARES	In-House (Pre-partnered)
	Dual GLP-2/GLP-1 agonist	Peptide	Intestinal failure / NASH	SOSEI HEPTARES	In-House (Pre-partnered)
	Apelin agonist	Peptide	Pulmonary Arterial Hypertension	SOSEI HEPTARES	In-House (Pre-partnered)
	Dual orexin antagonist	SME	Insomnia and sleep disorders	SOSEI HEPTARES	In-House (Pre-partnered)

In addition to the above, we are advancing an ever-growing list of In-House GPCR Programs through pre-discovery/discovery and early preclinical studies for large addressable patient populations

BUSINESS DEVELOPMENT



Sosei Heptares is recognized globally for challenging the frontiers of science, having solved more than 340 structures from more than 40 different GPCR targets. Large and untapped regions of the GPCR target universe, previously regarded as undruggable, are now tractable for rational drug discovery using our StaR® technology and SBDD platform. Our strategic focus is to leverage our world-leading technology platform and generate valuable, high quality novel clinical drug candidates which are attractive to innovative pharmaceutical and biotechnology companies.

RECENT DEALS



Tech collaboration for AI-powered and GPCR focused drug discovery (Jul-21)



Strategic collaboration and licensing agreement (Nov-21)



Tech collaboration for antibody discovery (Dec -21)



Research collaboration for AI-powered and GPCR focused drug discovery (Jan-22)



¹ Note: SME = small molecule; LME = large molecule; mAb = monoclonal antibody. ² Neurocrine will decide which selective M1 agonist program to prioritize. ³TPD: Targeted protein degradation

BOARD OF DIRECTORS

Mr. Shinichi Tamura

Chairman, President and CEO

Mr. Tomohiro Toyama

External Independent Director

Mr. Kuniaki Kaga

External Independent Director

Dr. David Roblin

External Independent Director

Mr. Noriaki Nagai

External Independent Director

Mr. Rolf Soderstrom

External Independent Director

EXECUTIVE OFFICERS

Mr. Shinichi Tamura

President and CEO

Dr. Malcolm Weir

Vice President

Mr. Chris Cargill

Chief Financial Officer

Dr. Tim Tasker

Chief Medical Officer

Mr. Kazuhiko Yoshizumi

Chief Compliance Officer

Mr. Tadoyashi Yasui

Executive Officer

SCIENTIFIC ADVISORY BOARD

Dr. David Roblin | Chair of Scientific Advisory Board



Dr. Peter Bernstein



Dr. Caetano Reis e Sousa



Prof. Ed Bullmore



Dr. Darryle Schoepp



Prof. Richard Henderson



Dr. Roberto Solari



Dr. Paul Leeson



Dr. Chris Tate



Prof. Sir Keith Peters



Mr. Anders Tullgren



Bristol-Myers Squibb

UK R&D MANAGEMENT



Mr. Shinichi Tamura

President and CEO

Genentech



Mr. Chris Cargill

Executive Officer, CFO



J.P.Morgan



Dr. Malcolm Weir

Executive Officer, Vice President



Dr. Tim Tasker

Executive Officer, Chief Medical Officer



Dr. Miles Congreve

Chief Scientific Officer



Dr. Rob Cooke

Chief Technology Officer



Dr. Barry Kenny

Senior Business Advisor



Mr. James Taylor


Chief Business Officer




FINANCIALS

(FX rate 1USD = 106 JPY)

FY2020 REVENUE (US\$M)



CASH POSITION (US\$M)



2021 FINANCIAL GUIDANCE

12 Months to 31-Dec-21	
Cash R&D Expenses	¥4,000–5,000M ~\$33-53M
Cash G&A Expenses	¥1,800–2,300M ~\$19-25M
Operational objectives	
<ul style="list-style-type: none"> Continue to expand expertise in GPCRs Generate at least 2 new preclinical candidates on average, every year Demonstrate progress of pipeline Add 2-3 new collaborations every year 	

SHARE INFORMATION

(As of 30 September 2021)


Core data

Listing	Tokyo Stock Exchange (Mothers)	Number of authorized shares	149,376,000
Company Name	Sosei Group Corporation	Number of issued common shares	81,518,316
Ticker symbol	4565-JP	Number of shareholders	27,769

Major shareholders¹

	Shareholders	Shareholding percentage (%)
Institutional investors ¹	Capital Group	9.88%
	Taiyo Pacific Partners	8.89%
	BlackRock Fund Advisors	1.21%
	Norges Bank Investment Management	0.79%
	Asset Management One	0.75%
	Mitsubishi UFJ Kokusai AM	0.75%
Other ²	Daisuke GOMI	7.86%
	Pfizer Inc.	2.31%
	Shinichi TAMURA	1.40%

Owner share distribution²



Source: ¹ FactSet/PREO Ownership Report, Report on large shareholders, ² Company Shareholders Report (as of 30 September 2021)

CONTACT US

Headquarters	PMO Hanzomon 11F, 2-1 Kojimachi, Chiyoda-ku, Tokyo 102-0083, Japan
Corporate Office	North West House, 119 Marylebone Road, London NW1 5PU, United Kingdom
R&D Facility	Steinmetz Building, Granta Park, Cambridge CB21 6DG, United Kingdom
Investor Relations	IR@SoseiHeptares.com
Communications	Comms@SoseiHeptares.com
Partnering	BusDev@SoseiHeptares.com

<https://soseiheptares.com>

[Twitter](#) [LinkedIn](#) [YouTube](#) @soseiheptaresco

sosei
HEPTARES